TJ Talks

The BENCHISTA – International  Benchmarking of Childhood Cancer Survival by Tumor stage – project is a worldwide collaboration led by University College London (UCL)  and Fondazione IRCCS Istituto Nazionale dei Tumori in Milan (INT) aiming to better understand the reasons behind international differences in paediatric cancer survival: the project highlights the importanc...

What emerges from the most recent first line trials is that the progress in advanced ovarian cancer depends not only on new treatment, but on the better patient selection: not all patients are in the same situation. And the most appropriate treatment must be determined for each individual: the best treatment for each patient. Within the complex clinical landscape of advanced ovarian cancer, the ne...

Caught between enthusiasm for technical innovation and the need for a critical assessment of research practices, the oncology is seeking a new path that offers real hope for effective treatments and a fair distribution of resources for the benefit of patients, because, as Prof. Gyawali’s elderly patient suggests, the real issue is that the quality of life depends entirely on the patient's pe...

Imparare a governare l'innovazione: questo l'invito che il cosiddetto Common Sense Oncology rivolge alla comunità oncologica per un approccio terapeutico interamente centrato sui bisogni del paziente. Alla base del ragionamento c'è una domanda semplice: siamo sicuri che più trattamento significhi sempre migliore medicina? E per comprendere cosa comporti trasformare questo...

From advances in the screening of prostate cancer to the management of the genitourinary tumors, the GU oncology addresses ever more clinical challenges.  What are the most relevant challenges in the management of the prostate cancer population? "It is crucial to balance the right treatment strategy with the right endpoint for patients": Professor Silke Gillessen gets straight to the poi...

The choice of an endpoint can really change the way a treatment is administered or approved for use on patients. And in the future, we will see much more data on quality of life, and trials will probably also work on validating surrogate endpoints and biomarkers.  In this TJ Talks dedicated to the hot topic of endpoints in clinical trials, Gabriele Zoppoli, Associate Professor of Medicine at...

Pharmaco-prevention of breast cancer is an evidence-based strategy that uses drugs to reduce the risk of disease in high-risk women. However, the use of this strategy remains modest due to concerns about toxicity, low awareness and difficulties in patient selection. In this TJ Talks podcast, together with Prof. Andrea De Censi, director of the Breast Unit at the Champalimaud Foundation in Lisbon,...

Stories of foreign cancer patients who ask to return to their country at the end of their lives: their deep desire to see their loved ones one last time is intertwined with medical, legal and financial issues that seem insurmountable. In this TJ Talks, Dr Sergio Defendi, director of Palliative Care and Home Care at Asst Crema, who has been providing assistance with end-of-life travel for years, di...

Storie di pazienti oncologici stranieri che chiedono di tornare nel loro Paese per il fine vita: attorno al desiderio profondo di rivedere ancora una volta i propri cari si intrecciano questioni mediche, legali, finanziarie che sembrano insormontabili. A parlarne in questo episodio di TJ Talks è il dr. Sergio Defendi, direttore S.C. Cure Palliative e Adi di Asst Crema, che da anni si occupa...

Looking forward to the future, the trends and challenges regarding the increasing utilization of real-world data and single-arm trials in the oncology drug approval pathway by European Medicines Agency (EMA) is very important, especially in the context of personalized medicine that will become the future. Dr. Francesco Pignatti, Scientific advisor for Oncology in the Human Medicine Divis...

Le parole del prof. Paolo Marchetti restituiscono il quadro complesso dell’oncologia di precisione con il ritmo epico delle grandi imprese di frontiera.  E’ lui - Professore Ordinario di Oncologia Medica dell’Università degli Studi di Roma “La Sapienza”, Direttore Scientifico di IDI-IRCCS, Presidente della Fondazione per la Medicina Personalizzata e promot...

In this episode of TJ Talks, the guest is Professor Paolo Marchetti, a well-known expert in precision oncology in Italy, Full Professor of Medical Oncology at the University of Rome "La Sapienza", Scientific Director of IDI-IRCCS, President of the Foundation for Personalized Medicine and promoter of the Trial of Rome clinical study. Precision oncology is a broad concept based on the study of the g...

If we were to stop at a first glance, the use of liquid biopsy would be limited in the clinical practice of colorectal cancer to cases where tumour tissue is unavailable or insufficient. In reality, we are at the beginning of a pathway where the true potential of liquid biopsy is developing rapidly in several directions. This is confirmed by the research results of Prof. Andrea Sartore Bianchi - D...

The field of bioinformatics is rapidly evolving, shaping the future of biomedical research and precision medicine. From cutting-edge advancements in computational biology to AI-driven solutions, what will the landscape look like in Italy in the coming years, and what opportunities will emerge for young bioinformaticians? In this TJ Talks event, the Bioinformatics Section Editor of Tumori Jour...

Drug resistance is a major challenge in oncology and genetically-engineered mouse models represent powerful tools to identify new approaches for its overcoming. In this TJ Talks podcast, Prof Paola Perego, Pharmacology Section Editor of Tumori Journal and Adjunct Professor at the University of Insubria, talks with Professor Sven Rottenberg, head of the Institute of Animal Pathology at the Universi...

Dr. Arsela Prelaj is confident: the implementation of Artificial Intelligence in Oncology, in the near future, will be aimed at advances in screening and the use of images, such as radiomics; in digital pathology, for a diagnostic task, and in applying Large Language Model for automation tasks. However, there will be climbs to overcome along the way. In this TJ Talks podcast, Dr Arsela Prelaj, Tho...

In this TJ Talks podcast, Dr Luca Agnelli, Tumori Journal Section Editor for Bioinformatics, meets Prof George Calin, a distinguished scientist with an extraordinary career dedicated to studying microRNAs, non-coding RNAs, and their impact on cancer. Listening to their exciting conversation, you will be engaged in the Prof. Calin's diverse research experiences across Eastern Europe, Western E...

A scientific society for integrating all aspects of cancer care - diagnostics, pathology, surgery, radiation, and medical oncology -through a multidisciplinary approach, because the future of medical oncology will focus on understanding cancer biology and intercepting the disease before it appears or recurs. In this TJ Talks, prof. Giuseppe Curigliano, chair of the Division of Early Drug Developme...

Evidence suggests that dietary interventions can effectively delay, treat and even prevent certain illnesses. This leads to the hypothesis that metabolic interventions might aid cancer treatment, and this is the focus of the conversation with one of the most distinguished researchers in the field. The guest of this episode of TJ Talks, hosted by prof. Giancarlo Pruneri, is dr. Claudio Vernieri, br...

The role of pathologists in precision oncology is increasingly recognised as central to effective cancer diagnosis and treatment. Their expertise in tumor classification and biomarker identification is crucial for the development of personalised therapies through advanced molecular biology techniques. To explore the unique aspects of the pathology postgraduate course at University of Milan, the Ed...

TJ Talks is an educational initiative featuring conversations about oncology led by Prof. Giancarlo Pruneri, Editor in Chief of Tumori Journal. The podcast series aims to explore a variety of topics of interest that reflect the dynamic and evolving nature of oncology research, with contributions from renowned international experts and promising young researchers in the field. Through these insight...